Advertisement
Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. (ITCI) Stock Competitors & Peer Comparison

See (ITCI) competitors and their performances in Stock Market.

ITCINASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$131.87
$0.00(0.00%)
U.S. Market is Open · 10:59
Advertisement

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ITCI$131.87+0.00%14B-180.64-$0.73N/A
TAK$15.87+0.83%49.7B41.37$0.38+3.96%
HLN$9.07+1.97%40.3B18.61$0.49+2.13%
TEVA$34.20+2.83%40.1B25.71$1.34N/A
VTRS$16.42+3.04%18.9B-54.00-$0.30+3.04%
ELAN$24.22+2.28%12.2B-49.00-$0.50N/A
CTLT$63.48+0.00%11.5B-27.84-$2.28N/A
RDY$13.33+0.72%11.1B24.76$0.54+0.69%
RGC$20.34-4.91%10B-2031.00-$0.01N/A
LNTH$103.85+3.84%6.5B23.86$4.19N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ITCI vs TAK Comparison June 2026

ITCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITCI stands at 14B. In comparison, TAK has a market cap of 49.7B. Regarding current trading prices, ITCI is priced at $131.87, while TAK trades at $15.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITCI currently has a P/E ratio of -180.64, whereas TAK's P/E ratio is 41.37. In terms of profitability, ITCI's ROE is -0.09%, compared to TAK's ROE of +0.03%. Regarding short-term risk, ITCI is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for ITCI.Check TAK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions